Mylan settles Viagra patent litigation with Pfizer
Mylan N.V. announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals Inc. reached a settlement and license agreement with Pfizer Inc., Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan’s Abbreviated New Drug Application or “ANDA” filed with the U.S. Food and Drug Administration for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction.
For the 12 months ending December 31, 2014, Viagra had U.S. sales of about $1.3 billion, according to IMS Health.